ABSTRACT: Introduction: This study aimed to identify infections in patients with myasthenia gravis, dermatomyositis, and chronic inflammatory demyelinating polyradiculoneuropathy, and to investigate the relationship between infection and immunomodulation. Methods: A retrospective chart review examined 631 patients with myasthenia gravis (n 5 358), chronic inflammatory demyelinating polyradiculoneuropathy (n 5 124), and dermatomyositis (n 5 149) patients over a 10-year time period. Results: Infection rates were similar at approximately 19% in all 3 diseases. Of the infections in which a causative organism was identified, pneumonia, sepsis, and opportunistic infections were the leading diagnoses. A multivariate model demonstrated a significant association between infection and an increased dose of plasma exchange, mycophenolate mofetil, and corticosteroid therapy. Discussion: There are few large studies investigating rates of infections in patients with autoimmune neuromuscular disorders and the relationship to immunomodulation. This study not only demonstrates the remarkably similar infection rates across the 3 diseases studied, but also shows their relationship to commonly used immunotherapies.
Myasthenia gravis, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and dermatomyositis are characterized by autoimmunity directed at various aspects of the neuromuscular system. The mainstay of treatment for autoimmune neuromuscular disorders is immunotherapy aimed at modulating or reducing disease activity. One of the most important considerations of immunosuppressive drug therapy is the increased risk of serious or life-threatening infections. [1] [2] [3] Earlier studies in inflammatory muscle disease have shown that 27%-37% of patients acquire significant infections, many of which are caused by opportunistic pathogens. 4, 5 Furthermore, these studies demonstrated that increased risk of infection was associated with various immunomodulatory treatments, including corticosteroids, azathioprine, and immunoglobulin therapies. 4 There are sparse data regarding susceptibility to infections in other autoimmune neuromuscular disorders and how rates of infection compare between disorders. Previous investigations in myasthenia gravis and CIDP have been mostly limited to reports of individual cases, and larger cohorts have been limited to inflammatory muscle disease. 4, 5 Herein we aimed to investigate the frequency and types of infections in patients with myasthenia gravis, dermatomyositis, and CIDP and the relationship of infection acquisition to treatment with commonly used immunomodulatory therapies.
METHODS
Study Population. This study was approved by institutional review board of the Ohio State University. Written informed consent was waived. All enrolled patients were followed in the Department of Neurology at the Ohio State University Wexner Medical Center from 2006 to 2015. The patients were identified by the Information Warehouse honest broker program based on billing records and diagnostic codes of myasthenia gravis (ICD-9 358.00 and 358.01), CIDP (357.81), and dermatomyositis (710.3).
Data Collection. Medical records were reviewed from the date of diagnosis until death, loss to follow-up, or the end of the study period. These records consisted of ambulatory encounters, inpatient admissions to the Ohio State University Hospital system, and outside records that had been copied into the chart. The following data were collected: age of disease onset; age at the conclusion of the study; gender; neuromuscular diagnosis; infection type and associated microorganisms (if identified); dates of infections; number of hospitalizations before infections; immunomodulatory treatments [corticosteroids, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, cyclophosphamide, plasmapheresis, and intravenous immunoglobulin (IVIg)]; and treatment dosage and duration.
Infections. Specific infections evaluated in the study consisted of pneumonia, sepsis, herpes zoster infections, soft tissue infections, line infections, bacteremia, colitis, oral infections, osteomyelitis, central nervous system (CNS) infections, fungemia, septic arthritis, pyelonephritis, endocarditis, and device infections. Opportunistic infections were defined as per the Centers for Disease Control criteria as applied to HIV/AIDS patients and included the following: CMV (cytomegalovirus) pneumonia and colitis; Candida pneumonia, esophagitis, and fungemia; herpes zoster, zoster ophthalmicus, and zoster iritis; Cryptococcus meningitis and fungemia; Epstein-Barr virus diffuse B-cell CNS lymphoma; Histoplasma fungemia; tuberculosis; toxoplasmosis; and Pneumocystis pneumonia. Infections were diagnosed clinically, and often with supportive cultures and clinical response to appropriate antibiotic therapy. For each infection we recorded the type, site, associated microorganisms, patient age at the time of infection, number of previous hospitalizations before infection, and immunomodulatory therapy before and at the time of infection. Minor, self-limited infections, including upper respiratory infections, gastroenteritis, superficial skin infections, and urinary tract infections, were excluded from data analysis.
Statistical Analysis. Patient demographics were identified at study onset. Cox proportional hazards regression models were fit for the time to infection, which is intervalcensored because only the year in which the infection occurred was accessible. The baseline hazard function was estimated using cubic splines with 4 knots. 6 Univariate associations were estimated of a patient's diagnosis and exposure to each drug and the time to infection. A multivariate model that included diagnosis and all drug exposures adjusted for age and sex was then considered. To calculate drug exposure, for each therapy a dose unit was first defined. One dose unit was defined as the average dose of a medication used in standard clinical practice for 1 year, as shown in Table S1 (refer to Supplementary Material, available online). The patient's cumulative exposure from initiation of therapy until the time of infection or the conclusion of the study was calculated in dose units. The average annual exposure was then calculated by dividing the cumulative dose of each drug in dose units by the follow-up time of the patient, which is the time to infection or the time to the conclusion of the study period. We also conducted the same analyses using binary indicators of patient exposure to each drug. Patients diagnosed with more than one of the autoimmune diseases, diagnosed with polymyositis, or treated with cyclophosphamide were excluded due to a small number of observed patients with those attributes. SAS version 9.4 software (SAS Institute, Inc., Cary, North Carolina) was used for all analyses.
RESULTS
Patients' Demographics. Charts of 631 patients with autoimmune neuromuscular disorders were included for review. Table 1 summarizes the demographics of these patients based on disease group (myasthenia gravis, dermatomyositis, and CIDP). Of the patients, 121 (19.2%) acquired significant infections, and 54 patients developed 2 or more infections, resulting in a total of 215 documented infections. Infection rates across disease groups were roughly identical at 19% in myasthenia gravis [95% confidence interval (CI) 15%-24%; CIDP, 95% confidence interval 13%-27%], and dermatomyositis (95% CI 13%-26%).
Types of Infections. Pneumonia was the most common infection (n 5 49), followed by sepsis (n 5 37). Of the 119 infections in which microorganisms were identified, there were 10 infections with multiple causative microorganisms. Of the microorganisms identified, 78 were bacterial, 30 viral, 19 fungal, and 2 parasitic. The most common microorganisms were varicella zoster virus (n 5 25), Staphylococcus aureus (n 5 23), Candida albicans (n 5 12), and Pseudomonas aeruginosa (n 5 12). Opportunistic infections comprised 37% (n 5 44) of all infections in which a microorganism was identified. The most common organisms causing opportunistic infections were varicella zoster virus (n 5 25) and Candida albicans (n 5 5).
Immunomodulation Exposure and Infection Rates. The proportion of patients exposed to each drug and mean average annual exposure are shown in Table 2 . Note that 90% of patients received multiple drugs. The odds of infection were 37% higher in those who received multiple drugs, but this was not statistically significant (odds ratio 5 1.37, 95% CI 0.68-2.77, P 5 0.3801). Estimated associations from the univariate analyses and multivariate model, including drug exposures, age, sex, and diagnosis, are shown in Table 3 . The hazard of infection did not differ significantly across disease type (myasthenia gravis, CIDP, and dermatomyositis) (P 5 0.8746).
As shown in Table 3 , a multivariate model, adjusted for age, sex, and diagnosis, demonstrated a significant association between infection and a 1-SD increase in dose to plasmapheresis, mycophenolate mofetil, and corticosteroids. Females had a significant reduction in the hazard of infection compared with males (hazard ratio 5 0.66, 95% CI 0.45-0.97). Hazard rates did not differ significantly across disease groups (P 5 0.75) or age (P 5 0.4837).
Estimates from the analysis with binary indicators of exposure are also shown in Table 3 . We found similar associations to those observed in the analysis with continuous doses, with the exception of for cyclosporine and methotrexate, likely due to the right skewed nature of the distribution of patient doses of these 2 treatments.
DISCUSSION
One of the potential complications in the treatment of autoimmune disorders is serious or lifethreatening infection due to immunomodulatory therapy. Our data in myasthenia gravis, CIDP, and dermatomyositis show that a significant proportion of patients have infections, and this frequency is similar to that noted in earlier studies that focused solely on dermatomyositis. 4, 5 The percentage of patients acquiring infections was roughly identical in all 3 diagnoses (19%).
In addition to characterizing the frequency and types of infections in patients with autoimmune neuromuscular disorders, the present study has also demonstrated a significant association between infection and plasmapheresis, mycophenolate mofetil, and corticosteroids. Infection rates in plasmapheresis could be, in part, related to the intravenous route that may lead to line infections in some cases. Whereas other immunomodulatory agents are often tapered more quickly due to side effects, mycophenolate mofetil may be better tolerated, leading to higher cumulative doses, which may account for the increased likelihood of infection. Hazard ratios, however, did not differ significantly across disease groups (P 5 0.75). Previous studies have shown an association between infection in inflammatory myopathy and exposure to IVIg and azathioprine, as well as an association between infection in myasthenia gravis and mycophenolate mofetil and azathioprine treatments. 4, [7] [8] [9] Studies in multiple sclerosis patients treated with long-term corticosteroids have shown increased rates of viral, bacterial, fungal, and parasitic infections. 10 In this study, opportunistic infections comprised over a third of all infections in which a causative microorganism was identified, with the most common being varicella zoster virus. Varicella zoster infections have been reported often in the context of high-dose systemic steroid therapy but not as frequently as reported here in our series. 11, 12 Such findings raise the question as to whether patients with autoimmune neuromuscular disease should be vaccinated for varicella zoster or be started on prophylactic antiviral therapy. Although, in this study, only a few cases of tuberculosis were documented, screening for tuberculosis may also be a cost-effective mechanism in preventing disseminated disease in this population. Previous studies have reported rates of opportunistic infections ranging from 10.9% to 21.3%. [13] [14] [15] [16] Few studies, however, have quantified opportunistic infection risk in myasthenia gravis and CIDP. Of note, the use of empiric trimethoprim- sulfamethoxazole as prophylaxis against Pneumocystis pneumonia in patients on long-term steroid therapy has been controversial. There are no consensus guidelines either within the neurological or rheumatological community. 17, 18 However, some neurologists have argued for the use of prophylaxis in patients prescribed a daily prednisone dose of 20 mg or more of at least 1-month duration. 18 Others have advocated for prophylaxis in dermatomyositis patients with a total lymphocyte count of less than 800 and/or CD4 lymphocyte counts of less than 400/L at the time of diagnosis. 19 Further adding to the urgency of the problem is the high fatality rate of Pneumocystis pneumonia once it is acquired.
There are some limitations to this study. First, this was a retrospective study of medical records at a single institution and may not reflect the general population. In addition, we considered the exposures to immunomodulating therapies as cumulative doses (during the study period), and were not able to account for the temporal relationship between the onset of infection and the dosing of drugs. Given the lack of knowledge about the exact timing of the infection diagnosis, we used interval-censored Cox models, which rely on the fact that we only know a time interval in which an infection occurred. Regarding the dosing of therapy, we did not know whether or when regimens changed, either in dose or by addition or subtraction of an additional therapy. Instead, we assumed that the regimen was constant throughout a patient's duration of disease. In an effort to illustrate sensitivity to this assumption, we presented the same analyses with binary indicators of drug exposure. For many of the immunomodulatory medications the dose remained fairly consistent throughout a patient's disease course; however, for others, such as corticosteroids or IVIg, there were more frequent dose adjustments. This study has provided only a coarse overview of the association between infection and immunomodulatory therapies, but it serves as a useful guidepost when counseling patients with myasthenia gravis, CIDP, or dermatomyositis on the very real infectious risks of various immunomodulatory therapies. Future studies that identify the onset of infections relative to initiation of treatment would be helpful in guiding clinicians who use these immunomodulatory agents over time. Further studies that correlate white blood cell and lymphocyte counts to measure potential increased susceptibility to infection may also contribute valuable data.
According to the dictum primum non nocere (do no harm), healthcare providers of patients with autoimmune neuromuscular disorders amenable to immunomodulatory therapy must carefully weigh the risks and benefits of the various agents. Increased risk of infection in patients with autoimmune disorders has generally been attributed to a direct effect of immunosuppression during immunomodulatory treatments, but it has also been postulated that immune dysregulation directly related to the pathogenesis of autoimmunity may play a role. 20 Thus, other factors not related to treatment may contribute to increased infection risk, and future studies should be designed to investigate baseline infection risk in patients with autoimmune disorders.
In conclusion, this study has revealed a significant but similar infection rate in 3 autoimmune neuromuscular diseases. We have demonstrated an association between treatment with immunomodulatory therapy (plasmapheresis, mycophenolate mofetil, and corticosteroids) and development of infections. This underscores the importance of careful consideration and thorough discussion with patients before initiation of immunomodulatory therapy and the consideration of use of prophylaxis against common or serious opportunistic infections.
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